Last $2.22 USD
Change Today +0.02 / 0.91%
Volume 190.4K
TSPT On Other Exchanges
As of 3:56 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

transcept pharmaceuticals in (TSPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/1/14 - $3.83
52 Week Low
08/29/13 - $1.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

transcept pharmaceuticals in (TSPT) Related Bloomberg News

View More Bloomberg News

transcept pharmaceuticals in (TSPT) Related Businessweek News

No Related Businessweek News Found

transcept pharmaceuticals in (TSPT) Details

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. The company principal product include Intermezzo sublingual tablet C-IV, a sublingual formulation of zolpidem for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Its lead product candidate is TO-2070, a rapidly absorbed treatment for acute migraine. The company has a collaboration agreement with Purdue Pharmaceutical Products, L.P. for the commercialization of Intermezzo in the United States, as well as granted the right to negotiate for the commercialization of Intermezzo in Mexico and Canada. Transcept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Point Richmond, California.

8 Employees
Last Reported Date: 03/14/14
Founded in 2002

transcept pharmaceuticals in (TSPT) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $560.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $350.0K
Chief Business Officer and Senior Vice Presid...
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2013.

transcept pharmaceuticals in (TSPT) Key Developments

Transcept Pharmaceuticals Announces Management Changes

Transcept Pharmaceuticals agreed to merge with Paratek. The board of directors of both Transcept and Paratek have unanimously approved the transaction. The merger is expected to close during the second half of 2014. The executive officers of Transcept will resign from their positions with Transcept upon the closing of the merger, and the executive officers of Paratek will assume their respective positions in Transcept. Michael F. Bigham, Partner at Abingworth, has been appointed as Chairman of the Board of Directors and Chief Executive Officer. In addition, Dr. Evan Loh, Chief Medical Officer (CMO) at Paratek, has been promoted to President and CMO and will continue to serve on the Board of Directors.

Paratek Pharmaceuticals, Inc., Transcept Pharmaceuticals, Inc. - M&A Call

To discuss the proposed transaction

Transcept Pharmaceuticals, Inc., Annual General Meeting, Jul 01, 2014

Transcept Pharmaceuticals, Inc., Annual General Meeting, Jul 01, 2014., at 08:30 Pacific Standard Time. Location: 1003 West Cutting Blvd. Agenda: To elect Matthew M. Loar, Jake R. Nunn and Glenn A. Oclassen as class II directors to serve for three-year terms and until their successors are duly elected and qualified; to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2014; to approve the tax benefit preservation plan; to consider an advisory vote to approve executive compensation; and to transact such other business as may properly be brought before the meeting and any postponement or adjournment thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TSPT:US $2.22 USD +0.02

TSPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Neurocrine Biosciences Inc $15.28 USD -0.305
Pfizer Inc $28.91 USD -0.03
Sanofi €79.28 EUR -0.47
Takeda Pharmaceutical Co Ltd ¥4,687 JPY -4.00
Vanda Pharmaceuticals Inc $12.30 USD -0.54
View Industry Companies

Industry Analysis


Industry Average

Valuation TSPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.2x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSCEPT PHARMACEUTICALS IN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at